Across TCGA pan-cancer cohorts, MIRLET7G RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated MIRLET7G data layer.
The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher MIRLET7G RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated MIRLET7G expression acts as an unfavorable survival marker, although some lineages such as PAAD and LAML show a favorable association.
PAAD, UVM, and UCS are the cancer types where MIRLET7G RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.